このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Arch Biopartners 将来の成長

Future 基準チェック /16

Arch Biopartnersの収益は成長。EPSは減少すると35.3%年率で予測されます。

主要情報

n/a

収益成長率

-35.3%

EPS成長率

Life Sciences 収益成長	16.3%
収益成長率	15.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	09 Apr 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

OTCPK:ACHF.F - アナリストの将来予測と過去の財務データ ( )CAD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2025	2	N/A	N/A	N/A	1
9/30/2024	2	N/A	N/A	N/A	1
3/31/2024	2	-2	0	0	N/A
12/31/2023	2	-2	0	0	N/A
9/30/2023	2	-3	0	0	N/A
6/30/2023	2	-4	2	2	N/A
3/31/2023	2	-3	1	1	N/A
12/31/2022	1	-3	-1	-1	N/A
9/30/2022	1	-1	0	0	N/A
6/30/2022	3	0	0	0	N/A
3/31/2022	5	0	-4	-4	N/A
12/31/2021	4	0	-1	-1	N/A
9/30/2021	4	-1	-3	-3	N/A
6/30/2021	2	-3	-4	-4	N/A
3/31/2021	0	-7	-2	-2	N/A
12/31/2020	0	-6	-2	-2	N/A
9/30/2020	0	-5	-2	-2	N/A
6/30/2020	0	-4	-2	-2	N/A
3/31/2020	0	-2	-2	-2	N/A
12/31/2019	0	-2	-2	-2	N/A
9/30/2019	0	-2	-2	-2	N/A
6/30/2019	0	-2	-2	-2	N/A
3/31/2019	N/A	-3	-2	-2	N/A
12/31/2018	N/A	-3	-2	-2	N/A
9/30/2018	N/A	-3	-2	-2	N/A
6/30/2018	N/A	-3	-2	-2	N/A
3/31/2018	N/A	-2	-1	-1	N/A
12/31/2017	N/A	-2	N/A	-1	N/A
9/30/2017	N/A	-2	N/A	-1	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	-1	N/A	-1	N/A
9/30/2016	N/A	-1	N/A	-1	N/A
6/30/2016	0	-1	N/A	-1	N/A
3/31/2016	0	-1	N/A	-1	N/A
12/31/2015	0	-1	N/A	-1	N/A
9/30/2015	0	-1	N/A	0	N/A
6/30/2015	0	-1	N/A	-1	N/A
3/31/2015	0	-1	N/A	0	N/A
12/31/2014	0	-1	N/A	0	N/A
9/30/2014	0	0	N/A	0	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A
9/30/2013	0	0	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACHF.Fの予測収益成長が貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: ACHF.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: ACHF.Fの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: ACHF.Fの収益 ( 15.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ACHF.Fの収益 ( 15.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACHF.Fの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Arch Biopartners 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Recent updates

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘